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Prostacyclin (PGI2) controls platelet activation and thrombosis througha cyclic adenosine monophosphate (cAMP) signaling cascade.However, in patients with cardiovascular diseases this protective
mechanism fails for reasons that are unclear. Using both pharmacological
and genetic approaches we describe a mechanism by which oxidized low
density lipoproteins (oxLDL) associated with dyslipidemia promote platelet
activation through impaired PGI2 sensitivity and diminished cAMP signal-
ing. In functional assays using human platelets, oxLDL modulated the
inhibitory effects of PGI2, but not a phosphodiesterase (PDE)-insensitive
cAMP analog, on platelet aggregation, granule secretion and in vitro throm-
bosis. Examination of the mechanism revealed that oxLDL promoted the
hydrolysis of cAMP through the phosphorylation and activation of PDE3A,
leading to diminished cAMP signaling. PDE3A activation by oxLDL
required Src family kinases, Syk and protein kinase C. The effects of oxLDL
on platelet function and cAMP signaling were blocked by pharmacological
inhibition of CD36, mimicked by CD36-specific oxidized phospholipids
and ablated in CD36-/- murine platelets. The injection of oxLDL into wild-
type mice strongly promoted FeCl3-induced carotid thrombosis in vivo,
which was prevented by pharmacological inhibition of PDE3A.
Furthermore, blood from dyslipidemic mice was associated with increased
oxidative lipid stress, reduced platelet sensitivity to PGI2 ex vivo and dimin-
ished PKA signaling. In contrast, platelet sensitivity to a PDE-resistant
cAMP analog remained normal. Genetic deletion of CD36 protected dys-
lipidemic animals from PGI2 hyposensitivity and restored PKA signaling.
These data suggest that CD36 can translate atherogenic lipid stress into
platelet hyperactivity through modulation of inhibitory cAMP signaling.   
Atherogenic lipid stress induces platelet
hyperactivity through CD36-mediated
hyposensitivity to prostacyclin: the role of
phosphodiesterase 3A 
Martin Berger,1,2,3 Zaher Raslan,3* Ahmed Aburima,1* Simbarashe Magwenzi,1
Katie S. Wraith,1 Benjamin E.J. Spurgeon,3 Matthew S. Hindle,3 Robert Law,1
Maria Febbraio4 and Khalid M. Naseem1,3
1Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University
of Hull, Hull, UK;  2Department of Internal Medicine 1, University Hospital RWTH
Aachen, Aachen, Germany; 3Discovery and Translational Science Department, Leeds
Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK and
4School of Dentistry, University of Alberta, Edmonton, AB, Canada
*ZR and AA contributed equally to this work  
ABSTRACT
Introduction
Myocardial infarction (MI) is characterized by platelet-driven atherothrombotic
events that lead to acute occlusion of a coronary vessel. Excessive platelet activation
is controlled by endothelial derived nitric oxide (NO) and prostacyclin (PGI2),1 but
action of these protective agents is overcome in MI by mechanisms that are yet to
be elucidated. A key risk factor for MI is dyslipidemia, which is strongly associated
with a pro-thrombotic phenotype linked to atherothrombosis and platelet hyperac-
tivity.2,3 The blood of high-risk individuals with dyslipidemia is characterized by
increased plasma lipid peroxides, with low density lipoproteins (LDL) serving as a
highly abundant carriers for these oxidatively-modified lipids.4–6 Oxidized LDL
(oxLDL) are circulating pathological ligands that can enhance thrombosis through
their ability to promote platelet hyperactivity. In vitro
experimentation demonstrates that these modified
lipoproteins can cause direct activation of platelets and
also potentiate platelet activation induced by physiologi-
cal agonists such as thrombin, ADP and epinephrine.7–10
However, the potential pathophysiological importance of
these observations for thrombosis in vivo remain unclear.
The scavenger receptor CD36 has emerged as a poten-
tial conduit for transducing plasma lipid stress into platelet
hyperactivity and thrombosis, through the recognition of
lipoprotein associated molecular patterns (LAMPs). CD36,
alone or potentially in combination with Toll-Like
Receptor (TLR)2 and TLR6 drive a complex series of intra-
cellular signaling events that are associated with platelet
activation.11–15 Upon ligation of CD36, Src family kinases
constitutively associated with the receptor, drive the acti-
vation of Syk, Vav-1, PLCγ2, ERK5 and JNK that are asso-
ciated with platelet activation.13,16–18 More recently, data
have emerged to suggest that the signaling events pro-
mote the generation of reactive oxygen species (ROS).14,16,17
ROS in turn activate ERK to drive thrombosis directly by
platelet hyperactivity and caspase-dependent procoagu-
lant activity.18,19 Moreover, we found that ROS diminish
sensitivity to the nitric oxide (NO)-stimulated cGMP-PKG
inhibitory signaling cascade to reduce the threshold for
platelet activation.17 These data suggest that the transla-
tion of atherogenic lipid stress by platelet CD36 is func-
tionally linked to both stimulation of activatory signaling
pathways and to an as of yet ill-defined modulation of
inhibitory pathways. 
PGI2 is the most potent endogenous regulator of platelet
function with both genetic and pharmacological modula-
tion of the pathway linked to accelerated thrombosis in
vivo.20 PGI2 activates a cyclic adenosine monophosphate
(cAMP) signaling pathway that leads to subsequent activa-
tion of protein kinase A (PKA) in platelets and results in
the phosphorylation of numerous proteins,21 linked to the
inhibition of Ca2+ mobilization, dense granule secretion,
spreading, integrin αIIbβ3 activation and aggregation in
vitro.20 To ensure optimal platelet function, cAMP levels are
tightly regulated by the hydrolyzing enzymes phosphodi-
esterase (PDE)2A and 3A. The pharmacological inhibition
or genetic ablation of PDE3A in murine and human
platelets reduces thrombotic potential.22,23 Thus, factors
that alter platelet inhibition by influencing cAMP synthe-
sis or hydrolysis may be critical modulators of
atherothrombosis and potentially lead to a pro-thrombot-
ic phenotype. Given the established link between oxi-
dized lipid stress and excessive platelet activation, the aim
of this study was to determine if oxidatively modified
lipoproteins could promote platelet hyperactivity through
modulation of the PGI2 /cAMP signaling pathway.
Methods
Reagents
Phospho-PKA Substrate (RRXS*/T*) Rabbit mAb and phospho-
VASP-Ser157/239 antibodies were from Cell Signaling Technology
(Danvers, USA). PDE3A antibodies were from the MRC Unit
(Dundee University, Dundee, UK). Anti-β-Tubulin antibody was
from Millipore (Nottingham, UK). BD Phosflow Lyse/Fix Buffer
was from BD Biosciences (Oxford, UK). OxPC-E06 mAb was
from Avanti Polar Lipids (Alabaster, USA). FITC-labeled Rat Anti-
Mouse P-selectin (CD62P) and PE-labeled JON/A antibodies were
from Emfret Analytics (Würzburg, Germany). Alexa-Fluor 647
Goat anti-Rabbit IgG, Alexa-Fluor 488 Succinimidyl Ester and
Pacific Blue Succinimidyl Ester were from ThermoFisher Scientific
(Waltham, USA). PAR-1 peptide was from Anaspec (Fremont,
USA). Anti-CD36 Antibody (FA6-152) was from Abcam
(Cambridge, UK). Phosphodiesterase Activity Assay Kit was from
Enzo Life Sciences (Exeter, UK). cAMP Biotrack EIA was from GE
Healthcare (Buckinghamshire, UK). Horm Collagen was from
Nycomed (Munich, Germany). PGI2 and Cholesterol Assay Kit
were from Cayman Chemical (Cambridge, UK). Vena8
Endothelial+ biochips were from Cellix (Hertfordshire, UK). All
other reagents were from Sigma-Aldrich (Dorset, UK).
Experimental animals
CD36-/- mice were provided by Prof. Maria Febbraio (University
of Alberta, Canada). C57BL/6 were from Charles River (Kent, UK).
For high-fat diet studies, male mice were fed a 45% Western diet
(Special Diet Services) for 12–16 weeks. Sex/age-matched litter-
mates were fed a normal chow for the duration of the experiments
and used as controls. For all remaining experiments, male C57BL/6
and CD36-/- were used at eight weeks of age. 
Isolation and oxidation of plasma low density 
lipoproteins 
Low-density lipoproteins (density 1.019–1.063 g/mL) were pre-
pared from fresh human plasma by sequential density ultracen-
trifugation and oxidised with CuSO4 (10 mmol/L).14 Separate
preparations of LDL were used to repeat the individual experi-
ments.
Platelet aggregation, flow assays, flow cytometric
analysis, intravital microscopy, immunoprecipitation,
immunoblotting, phosphodiesterase enzyme activity
assay and cyclic adenosine monophosphate measure-
ment
Detailed methods are presented in the Online Supplementary
Methods. 
Statistical analysis
Experimental data was analyzed by Graphpad Prism 6 (La Jolla,
CA, USA). Data are presented as means±standard error of the
mean (SEM) of at least three different experiments. Differences
between groups were calculated using Mann-Whitney U Test or
Kruskal-Wallis Test for non-parametric testing and statistical sig-
nificance accepted at P≤0.05. 
All studies were approved by the Hull York Medical school
Ethics committee and University of Leeds Research Ethics com-
mittee.  
Results
Oxidized low density lipoproteins cause platelet
hyposensitivity to  prostacyclin
Treatment of human washed platelets with PGI2 (20
nM) for one minute (min), at a time point that induces
maximal cAMP-mediated signaling24 reduced thrombin
(0.05 U/mL)-induced aggregation from 89.0±4.1 to
9.4±4.4% (P<0.01) (Figure 1A). Next, platelets were treat-
ed with oxLDL or control native LDL (nLDL) (50 mg/mL)
for 2 min prior to the addition of PGI2 (20 nM) and throm-
bin (0.05 U/mL). The presence of oxLDL caused a partial
recovery in thrombin-stimulated platelet aggregation to
50.0±9.3 (P<0.015 vs. control), without stimulating aggre-
gation directly (Figure 1A). In contrast, PGI2-mediated
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haematologica | 2020; 105(3) 809
M. Berger et al.
810 haematologica | 2020; 105(3)
Figure 1. Oxidized low-density lipoproteins (oxLDL) induce prostacyclin (PGI2) hyposensitivity in platelets. (A) Washed human platelets (2.5 x 108/mL) were treated
alone or with control native LDL (nLDL) or oxLDL (50 mg/mL) for 2 minutes (min) followed by a 1 min incubation with PGI2 (20 nM). Thrombin (0.05U/mL)-stimulated
aggregation was then measured under constant stirring (1000 rpm) at 37°C for 4 min. In some cases, platelets were incubated with either thrombin, nLDL or oxLDL
alone for 4 min. (Left) Representative aggregation traces. (Right) Percentage aggregation is presented by mean±standard error of mean (SEM) (n= 5). **P<0.01
compared to platelets treated with thrombin and PGI2, Mann-Whitney U Test. (B) Whole blood was treated as in (A) and activated with PAR-1 peptide (10 µM) for 5
min followed by fixation. CD62P expression was assessed by flow cytometry. Representative data of three independent experiments. (Left) Data are presented as
heatmap of mean fluorescence intensity (MFI). (Right) Representative histograms. (C) Human whole blood was incubated with PGI2 (20 nM) for 1 min alone or with
control native LDL (nLDL)  or oxLDL (50 mg/mL) for 10 min. Blood was perfused over collagen-coated biochips for 2 min at arterial shear 1000s-1 and images of
adherent platelets were taken by fluorescence microscopy. (Left) The surface coverage (%) is presented as mean±SEM (n=3) (P<0.05, Mann-Whitney U Test). (Right)
Representative fluorescence microscopy images are shown. (D) Whole blood was incubated with nLDL or oxLDL (50 mg/mL) for 10 min and then perfused over col-
lagen-coated surfaces for 2 min at arterial shear 1000s-1. Thrombi were post-stained with anti-oxPC antibody and images were taken by fluorescence microscopy.
(Left) Representative of images of 3 independent experiments. Stained with DIOC6 (top panel) or anti-oxPC (bottom panel) (Center) The surface coverage is present-
ed as mean±SEM (n=4, *P<0.05, Mann-Whitney U Test). (Right) Fluorescence (red Channel) is presented as mean±SEM (n=4, *P<0.05, Mann-Whitney U Test).
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inhibition was unaffected by nLDL (5.8±1.2%). Similar
data were obtained when platelets were stimulated with
collagen (Online Supplementary Figure S1). Next, the effects
of oxLDL in whole blood were examined. Stimulation of
whole blood with PAR-1 peptide (10 mM) increased 
P-selectin expression, which was reduced by pre-treat-
ment with PGI2 (20 nM). Consistent with the aggregation
experiments, oxLDL reduced inhibitory effects of PGI2
(Figure 1B). Finally, the effects of oxLDL under physiolog-
ical conditions of arterial flow were examined. Perfusion
of whole blood over collagen-coated biochips led to
platelet deposition and thrombus formation (Figure 1C),
with surface coverage inhibited by PGI2 (20 nM) from
14.9±2.9 to 3.8±1.7% (P<0.05). OxLDL, but not nLDL,
prevented PGI2 -mediated inhibition of platelet deposition
(8.1±1.9%; P<0.05 compared to PGI2 alone). OxLDL alone
caused a small but non-significant increase in thrombosis
and was incorporated into the thrombi as evidenced by
staining for oxidized lipid epitopes (Figure 1D). These data
demonstrate that under a variety of different conditions
oxLDL reduces platelet sensitivity to PGI2.
Oxidized low density lipoproteins modulate cyclic
adenosine monophosphate signaling through
increased phosphodiesterase 3A activity
PGI2 inhibits platelets through the stimulation of cAMP-
PKA signaling cascade.20 Given the reduced platelet sensi-
tivity to PGI2, the direct effect of oxLDL on platelet cAMP
metabolism was tested. Incubation with PGI2 caused a sig-
nificant increase in platelet cAMP concentrations
(1814±166 fmol cAMP/1x108 platelets; P<0.05 vs. basal).
When platelets were treated with nLDL (50 mg/mL), the
ability of the prostanoid to elevate cAMP was unaffected
(1885±203 fmol cAMP/1x108 platelets), while oxLDL 
(50 mg/mL) prevented PGI2-induced accumulation of
cAMP (481±23 fmol cAMP/1x108 platelets; P<0.05 com-
pared to PGI2 alone) and also reduced basal cAMP concen-
trations (not significant) (Figure 2Ai). To determine if
oxLDL blocked cAMP synthesis or accelerated cAMP
breakdown by phosphodiesterase 3A (PDE3A) and
PDE225,25 the PDE2A inhibitor EHNA (20 mM) and the
PDE3A inhibitor milrinone (10 mM) were used. Consistent
with previous studies, both inhibitors potentiated cAMP
CD36 activates platelet PDE3A
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Figure 2. Oxidized low-density lipoproteins modulate cyclic adenosine monophosphate (cAMP) signaling in response to prostacyclin (PGI2). (A) Washed human
platelets (2x108/mL) incubated with apyrase, indomethacin and EGTA were treated alone or with control native LDL (nLDL) or oxLDL (50 mg/mL) for 2 minutes (min)
followed by a 1 min PGI2 (50 nM) incubation. Platelets were lysed and intracellular cAMP concentrations were measured by enzyme immunoassay. (Left) Intracellular
cAMP levels presented as mean±standard error of mean (SEM) (n=3, *P<0.05, Mann-Whitney U Test). (Center) Platelets treated as described under (A) in the pres-
ence EHNA (20 mM). Intracellular cAMP levels are presented as mean±SEM (n=3, *P<0.05, Mann-Whitney U Test) (Right) Platelets treated as described under (A) in
the presence of Milrinone (10 mM). Intracellular cAMP levels are presented as mean±SEM (n=3, *P<0.05, Mann-Whitney U Test). (B) Washed human platelets
(2x108/mL) were incubated alone or with oxLDL (50 mg/mL) for 2 min followed by a 5-min incubation with Forskolin (10 mM), then lysed and measured as described
under (A). Intracellular cAMP concentrations presented as mean±SEM (n=3, *P<0.05, Mann-Whitney U Test). (C) Washed human platelets (5x108/mL) were treated
as described under (A), lysed in Laemmli buffer, separated by SDS-PAGE and immunoblotted with anti-phosphoPKA substrate, anti-phosphoVASPser157 and anti-β
tubulin. (Left) Representative blot of three independent experiments. (Right) Densitometry of the representative highlighted band (red) (*P<0.05, Mann-Whitney U
Test). (D) Washed human platelets were treated as described under (A) except that platelets were treated with 8-CPT-cAMP (50 mM) for 5 min and then processed
as in (C). (Left) Representative blot of three independent experiments and (Righti) densitometry of the representative highlighted band (red).  
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Figure 3. Oxidized low-density lipoproteins (oxLDL) and oxPCCD36 alter prostacyclin (PGI2)  inhibitory signaling via CD36. (A) Washed human platelets (5x108/mL)
incubated with apyrase, indomethacin and EGTA were incubated with FA6-152 or IgG (1 mg/mL) for 20 minutes (min). Platelets were then incubated alone or with
control native LDL (nLDL) or oxLDL (50 mg/mL) for 2 min and subsequently stimulated by PGI2 (50nM) for 1 min. Treated platelets were lysed in Laemmli buffer, sep-
arated by SDS-PAGE and immunoblotted with anti-phosphoVASPser157 or anti-β tubulin. (Top) Representative blot of three independent experiments. (Bottom)
Densitometry of pVASPser157 fold-change above basal mean±standard error of mean (SEM) (n=3 *P<0.05, Mann-Whitney U Test). (B) As in (A) except that platelets
were probed for pVASPser239. (C) Platelets were treated as in (A) alone or with oxPCCD36 or PAPC (25 mM) for 2 min followed by PGI2 (50 nM) for 1 min. (Top)
Representative blot of three independent experiments and (Bottom) Densitometry of pVASPser157 fold-change above basal, mean±SEM (n=3 *P<0.05, Mann-
Whitney U Test). (D) Washed wild-type murine platelets (2.5x108/mL) were treated alone or with oxPCCD36 or PAPC (10 mM) for 2 min followed by a 1 min incubation
with PGI2 (20 nM). Thrombin (0.05 U/mL)-stimulated aggregation was then measured under constant stirring (1000 rpm) at 37°C for 4 min. (Top) Representative
aggregation traces and (Bottom) data presented as percentage aggregation, mean±SEM (n=3, P<0.05, Mann-Whitney U Test). (E) As described in (D) for CD36-/-
platelets. Ns: not significant. (F) Washed murine WT or CD36-/- platelets (2x108/ml) were treated alone or with nLDL or oxLDL (50 mg/mL) for 2 min followed by a 
1-min PGI2 (50 nM) incubation. Platelets were lysed, and intracellular cAMP concentrations were measured by enzyme  immunoassay. Intracellular cAMP levels are
presented as mean±SEM (n=3, *P<0.05, Mann-Whitney U Test). (G) As in (A) except that murine (Left) WT and (Right) CD36-/- platelets were used. Representative
blot of three independent experiments. pVASPser157 is presented as beta-tubulin corrected fold-change above basal±SEM (n=3 *P<0.05, Mann-Whitney U Test). 
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Figure 4. Oxidized low-density lipoproteins (oxLDL)  and oxPCCD36 induce sustained phosphodiesterase 3A (PDE3A) activity in a CD36-dependent manner. (A).
Washed human platelets (5x108/mL) incubated with apyrase, indomethacin and EGTA were (Left) incubated with nLDL (50 mg/mL) or oxLDL (10-100 mg/mL) for 2
minutes (min) or (Right) incubated with control native LDL (nLDL) (50 mg/mL) or oxLDL (50 mg/mL) for up to 60 min. Platelets were lysed, PDE3A was immunopre-
cipitated and enzyme activity was measured. Data is expressed as % activity above basal activity and presented as mean±standard error of mean (SEM) (P<0.05;
n=3, Kruskal-Wallis Test ). (B) Washed human platelets (5x108/mL) were incubated with oxLDL (50 mg/mL) for up to 60 min followed by PGI2 (50 nM) for 1 min.
Platelets were lysed, and intracellular cyclic adenosine monophosphate (cAMP)  levels were determined by enzyme immunoassay. Data are presented as mean±SEM
(*P<0.05, n=3, Kruskal-Wallis Test). (C) Washed human platelets  (5x108/mlL) were incubated with oxPCCD36 or PAPC (25 mM) for 2 min, and activity of immuno-
precipitated PDE3A measured. Data are expressed as % activity above basal activity and presented as mean±SEM (P<0.05; n=3 Mann-Whitney U Test).  (D) As in
(C), except that PDE3A activity was measured in wild-type (WT) and CD36-/- washed platelets (*P<0.05; n=3 Mann-Whitney U Test).  (E) As in (A) except that human
platelets (5x108/mL) incubated with apyrase, indomethacin and EGTA were then treated with oxPCCD36 or PAPC (25 mM) for 2 min in the presence of absence of
dasatinib (10 mM) or vehicle control (DMSO). PDE3A was immunoprecipitated, and enzyme activity was measured. Data are expressed as % activity above basal
activity and presented as mean±SEM (P<0.05; n=4 Mann-Whitney U Test). (F) As in (A) except that platelets were treated with R406 (1 mM) or vehicle control (DMSO).
(G) As in (A), except that platelets were treated with PKC inhibitors (RO31 10µM, BIM1 10µM), PMA (100nM), BAPTA (20 mM) or vehicle control (DMSO). (n=3,
*P<0.05 compared to basal, Kruskal-Wallis Test ). (H) Washed human platelets (5x108/mL) treated with apyrase, indomethacin and EGTA were incubated with or
oxLDL (50 mg/mL; 0-60 min) or thrombin (0.1 U/mL; 0-2min). Treated platelets were lysed in Laemmli buffer, separated by SDS-PAGE and immunoblotted with anti-
phosphoPDE3Aserr312, phosphoPDE3Aser428 or anti-β tubulin. (Left) Representative blot of three independent experiments. (Right) Densitometry for
phosphoPDE3Aser428 is presented as fold-change above basal, mean±SEM (n=3, *P<0.05, Kruskal-Wallis Test). 
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accumulation in response to PGI2 .26,28 OxLDL reduced
cAMP levels in the presence of EHNA (2645±122 to
488±7623 fmol cAMP/1x108 platelets; P<0.05), but failed
to prevent cAMP accumulation in the presence of milri-
none (4761±170 to 4386±15723 fmol cAMP/1x108
platelets; P<0.05 ) (Figure 2Aii and 2Aiii). To confirm that
the reduction in cAMP accumulation was not restricted to
PGI2, platelets were stimulated with forskolin, which
increases cAMP in a receptor-independent non-compart-
mentalized mechanism. Forskolin (10 mM)-stimulated ele-
vation in cAMP was prevented by preincubation with
oxLDL (9506±526 to 4506±1136 fmol cAMP/2x108
platelets; P<0.05) (Figure 2B).  
Next, the effects of oxLDL on cAMP signaling were
assessed. m (50 nM) induced robust phosphorylation of a
number of PKA substrates with apparent molecular
weights of: 150, 100, 75, 70, 50, 37 and 20kDa (Figure 2C
upper panel), and specifically vasodilator-stimulated phos-
phoprotein (VASP) (phosphoVASP-ser157) (Figure 2C mid-
dle panel) an established target of PKA signaling.27 These
phosphorylation events were diminished by oxLDL (50
mg/mL), but unaffected by nLDL (50 mg/mL) (Figure 2Cii).
To further establish that the reduced signaling response
was due to enhanced cAMP hydrolysis, the experiment
was repeated with 8-CPT-6-Phe-cAMP (50µM), a cell per-
meable non-hydrolysable (PDE resistant) analog of cAMP
(Online Supplementary Figure S2). Using a concentration
that produced an equivalent quantity of intracellular
cAMP  (Online Supplementary Figure S3) as m (50 nM), 8-
CPT-6-Phe-cAMP caused robust phosphorylation of PKA
substrates, which were unaffected by oxLDL (Figure 2D).
These data suggest that oxLDL may regulate platelet sen-
sitivity to m through modulation of the cAMP-signaling
cascade by PDE3A.  
CD36 is required for oxidized  low-density lipoprotein
modulation of cyclic adenosine monophosphate 
signaling
Previously, we and others have shown that CD36 trans-
duces the effects of oxLDL into platelet hyperactivi-
ty.14,18,28,29 To examine the role of CD36 in linking oxLDL to
altered cAMP signaling, we used a three-pronged strategy:
(i) the CD36-blocking antibody FA6-152; (ii) the oxidized
phospholipid oxPCCD36, a CD36-specific pathological
ligand present in oxLDL,26 and (iii) murine platelets defi-
cient in CD36 (Online Supplementary Figure S4). This strat-
egy, particularly the use of oxPCCD36, was used to
account for differences in human and murine platelet sen-
sitivity to human oxLDL. PGI2 induced a robust phospho-
rylation of both the preferred ser157 site and the alternative
PKA phosphorylation site ser239 in human platelets,30
which was reduced significantly by oxLDL. The presence
M. Berger et al.
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Figure 5. Oxidized low-density lipoproteins induced thrombosis in vivo is prevent by inhibition of phosphodiesterase 3A (PDE3A). Intravital microscopy was per-
formed as described in the Online Supplementary Methods.  (A) Representative fluorescence images of thrombi formed under different conditions are shown over
the course of 40 minutes (min) after vascular injury. Black arrow shows the direction of blood flow. (B) Representative median integrated fluorescence signals of
Rhodamine G obtained from an individual carotid thrombus under different conditions. (C) Quantified median integrated fluorescence signals from 10, 20, 30 and
40 min after vascular injury taken from five wild-type (WT) mice for each treatment. *P<0.05; **P<0.01, Kruskal-Wallis Test.
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Figure 6. High-fat diet fed mice correlate with increased plasma levels of oxidized phospholipids to reduced prostacyclin (PGI2) sensitivity via CD36. (A)
Representative dot blots of mouse plasma probed with anti-oxidized phospholipids (HRP-conjugated-E06) and total-IgG (HRP-conjugated anti-mouse). (B) Whole
blood from normal chow and high-fat fed animals were treated with PGI2 (100nM) for 1 minute (min). Blood was fixed, permeabilized and incubated with anti-
pVASPser157 followed by secondary fluorescent-conjugate (Alexa 647) and analyzed by flow-cytometry. Representative heat map of fold increase in
phosphoVASPser157. Quantification is presented as fold-change of median fluorescence intensity above basal (n=4, *P<0.05, Mann-Whitney U Test). (C) Whole blood
from normal chow and high-fat diet fed animals were treated with PGI2 (100 nM) for 1 min followed by CRP (10 mg/mL) for 5 min. Blood was fixed and JON/A positive
cells were analyzed by flow cytometry. (Left) Representative histograms. (Right) Data presented as percentage inhibition of JON/A binding, mean±standard error of
mean (SEM) (n=4 *P<0.05, Mann-Whitney U Test). (D) Whole blood incubated alone or with PGI2 (20 nM) for 1 min was perfused at arterial shear 1000s-1 for 2 min
over a collagen matrix (50 mg/mL). Images of adherent platelets were taken by fluorescence microscopy. (Top) surface coverage (%) presented as a function of time.
(Bottom left) Representative images of arterial flow experiments, (Bottom right) Data presented as inhibition of surface coverage (%), mean±SEM (n=5; *P<0.05,
Mann-Whitney U Test).  
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of FA6-152 (1 mg/mL), but not control IgG (1 mg/mL),
caused a significant recovery in phosphoVASP-ser157
(Figure 3A and B). OxPCCD36 (25 mM),  but not the con-
trol lipid, PAPC (25 mM), diminished phospoVASP-ser157
in response to PGI2 (Figure 3C). Thrombin-induced aggre-
gation of wild-type (WT) and CD36-/- platelets was indis-
tinguishable, and and PGI2 (20 nM) caused complete inhi-
bition of aggregation with only shape change remaining
(Figure 3D and E). However, in CD36-deficient platelets,
oxPCCD36 (25 mM) did not influence the inhibitory
effects of PGI2 (Figure 3E). To confirm the mechanism
underpinning these observations, we examined cAMP sig-
naling. PGI2 (20 nM) caused a significant increase in cAMP
in both WT and CD36-/- platelets (4382±175 and 4128±366
fmol cAMP/1x108 platelets). Preincubation with oxLDL,
but not nLDL, reduced cAMP accumulation in WT mice
(3347±294 fmol cAMP/1x108 platelets; P<0.05) but not
CD36-/- (4196±224fmol cAMP/1x108 platelets) (Figure 3F).
Furthermore, PGI2-induced phosphoVASP-ser157 (Figure
3G) and ser239 (Online Supplementary Figure S5) were
reduced by oxLDL in WT but not CD36-/- platelets. 
Atherogenic lipid stress induces platelet 
phosphodiesterase 3A activity through a mechanism
that requires CD36, Src kinases and  protein kinase C
Our data suggested that ligation of CD36 could activate
PDE3A. We tested this directly measuring enzymatic
activity of PDE3A immunoprecipitated from platelets
treated with either oxLDL or oxPCCD36. PDE activity in
the immunoprecipitated samples was blocked by milri-
none confirming enzyme activity was due to PDE3A
(Online Supplementary Figure S6). OxLDL (10-100 mg/mL)
caused a concentration-dependent increase in PDE3A
activity (Figure 4A, left), which plateaued at 50 mg/mL
(24±6.8%; P<0.05 compared to basal) and was maintained
at 27.7%±8.5 above basal for up to 60 min (longest time
tested) (Figure 4A, right). This was strikingly different
from the physiological agonist thrombin which induced a
rapid induction of PDE3A activity that peaked at 1 min
before returning to basal after 5 min (Online Supplementary
Figure S7). 
To link the sustained activation of PDE3A to decreased
cAMP levels, we assessed the cyclic nucleotide concentra-
tions over time. Platelets were incubated with oxLDL for
up to 60 min, followed by a 1 min treatment with PGI2 (50
nM) before measuring cAMP concentrations. The pre-
incubation of platelets with oxLDL, but not nLDL (data not
shown), for up to 60 min significantly blunted PGI2-induced
increases in cAMP with concentrations remaining at basal
levels for the time course (Figure 4B). To confirm the role
of CD36 in the activation of PDE3A, experiments were
repeated with oxPCCD36. In human platelets, oxPCCD36
(25 mM), but not PAPC (25 mM), increased PDE3A activity
(26.9±7.3%; P<0.05 compared to basal and PAPC) (Figure
4C). Critically, oxPCCD36 stimulated activity in WT
platelets to 25.4±2.4% (P<0.05 compared to basal or
PAPC) but not in CD36-/- platelets (Figure 4D). 
We previously described a CD36-specific signaling
pathway that includes the sequential activation of Src-
family kinases (SFK), Syk, PLCγ2 and protein kinase C
(PKC)17 and investigated whether these kinases were
involved in the activation of PDE3A. The non-selective
SFK inhibitor, dasatinib (10 mM), ablated oxPCCD36-
induced PDE3A activation (Figure 4E), while the Syk
inhibitor, R406 (1 mM), caused significantly reduced
PDE3A activity (Figure 4F). Given that CD36 signaling
leads to PKC activation in a SFK manner, and that PDE3A
is a target of PKC in platelets,31 we tested the PKC
inhibitors RO318220 (10 mM) and BIM1 (10 mM), and the
intracellular Ca2+ chelator BAPTA-AM (20 mM) (Figure
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Figure 7. Proposed signaling pathway downstream of CD36 through which oxidized low-density lipopro-
teins (oxLDL) activate phosphodiesterase 3A (PDE3A) to suppress cyclic adenosine monophosphate
(cAMP) signaling. OxLDL binds to CD36 to activate a tyrosine kinase signaling pathway that leads to a sus-
tained activation of PDE3A.  Under these conditions cAMP is maintained at low concentrations through
hydrolysis to 5’AMP (solid red line), and the activation of PKA is diminished (dashed red line). Through dis-
inhibition, this pathway acts to reduce the threshold for platelet activation and promote thrombosis. 
4G). These three inhibitors blocked PDE3A activity
induced by oxLDL, suggesting a PKC-dependent pathway
(P<0.05). Platelet PDE3A activation is associated with
phosphorylation of key serine residues.31 We examined
two of the most characterised sites, ser312 (PKA and PKC
sensitive) and ser428 (PKC sensitive). OxLDL led to a time-
dependent phosphorylation of ser428 which peaked at 2
min and was still evident at 10 min, but had no effect on
phosphoPDE3Aser312. In comparison, thrombin (0.1 U/mL)
induced significantly less phosphorylation at ser428, which
peaked at 1 min before returning to basal at 2 min (Figure
4H) but also induced phosphorylation of ser312. These
data confirm that oxLDL and its associated oxidized phos-
pholipids require the sequential ligation and activation of
CD36, Src, Syk and PKC to activate PDE3A.  
Dyslipidemia is associated with platelet prostacyclin
hyposensitivity in mice
To demonstrate the functional importance of our obser-
vations on dyslipidemia-driven thrombosis, we examined
platelet sensitivity to PGI2 in mice fed a Western diet
(45%). cAMP signaling, integrin αIIbβ3 activation and
thrombosis were assessed in whole blood ex vivo, which
allowed us to evaluate platelet function and thrombotic
potential while avoiding any confounding effects of
altered PGI2 synthesis in vivo associated with
dyslipidemia.32 Western diet significantly raised choles-
terol levels (Online Supplementary Figure S8) and the pres-
ence of oxidized phospholipids in the plasma (Figure 5A).
We then investigated the effect of dyslipidemia on cAMP
signaling using multiplexed phosphoflow cytometry to
allow the examination of signaling in the physiological
conditions of whole blood.24 Platelets from high-fat fed
WT animals produced significantly less phosphoVASP-
ser157 when challenged with PGI2 (100 nM) than normal
chow WT mice (4.9±0.4 fold vs. 6.2±0.2-fold increase over
basal; P<0.05) (Figure 5B). The deletion of CD36 protected
cAMP signaling in dyslipidemic blood, with
phosphoVASP-ser157 remaining at control levels (Figure 5B).
In parallel experiments, blood was stimulated with CRP-
XL (10 mg/mL) in the presence and absence of PGI2 (100
nM), and αIIbβ3 activation was measured. In normal
chow WT blood, PGI2 caused 75.7±3.9% inhibition of
integrin activation (P<0.05 compared to absence of PGI2),
which was blunted in high-fat fed WT blood (43.1%±7.6
inhibition, P<0.05 compared to normal chow) (Figure 5C,
left). Conversely, in CD36-/- blood, PGI2 induced inhibition
of integrin activation was not significantly different in nor-
mal chow and high-fat fed conditions (66.5±8% and
79.3±6.5%, respectively) (Figure 5C, 1st and 2nd left). 
When we assessed ex vivo thrombosis under flow, nor-
mal chow WT blood formed small thrombi on immobi-
lized collagen in a time dependent manner, which was
abolished by PGI2 (20 nM) (Figure 5Di). High-fat fed WT
blood showed an accelerated thrombotic response with
increased surface area (11±3.6% compared to 16.2±4.3%
at 2 mins). In addition, dyslipidemia caused significant
hyposensitivity to PGI2, with the prostanoid causing
31.7±10.7% inhibition compared 61.6±5.6% with normal
chow (P<0.05; 2 min) (Figure 5ii and iii). In contrast, accel-
erated platelet deposition on collagen and platelet
hyposensitivity to PGI2 was not detected in CD36-/- high-
fat fed blood (Figure 5D). We repeated the experiments
with 8-CPT-6-Phe-cAMP. If PDE3A activation was respon-
sible for the increased thrombotic potential associated
with reduced sensitivity to PGI2, then CPT-6-Phe-cAMP-
mediated inhibition of thrombosis would be unaffected
by dyslipidemia. The cAMP analog caused a similar
degree of inhibition of thrombosis in all genotypes but
critically remained unaffected in the context of dyslipi-
demia (WT-normal chow, 65.6±11.2%; WT-Western diet,
62.3±7.7%; CD36-/--normal chow, 70.4±2.0%; CD36-/--
Western diet, 62.3±5% inhibition) (Online Supplementary
Figure S9). Here we show a physiological role for platelet
CD36 in dyslipidemia, where it drives a phenotype of
platelet hyperactivity by blocking cAMP-mediated inhibi-
tion.
Oxidized low density lipoprotein potentiation of 
thrombosis in vivo is prevented by inhibition of 
phosphodiesterase 3A
To examine the role of oxLDL in thrombosis in vivo we
used intravital microscopy following ferric chloride–
induced carotid artery injury. Tail-vein injections of oxLDL
(2.5 mg/kg-1 bodyweight)33,34 into WT mice accelerated
post-injury thrombotic response at all time points com-
pared to control PBS injection (Figures 6A-C and Online
Supplementary Videos S1 and S2). Next animals were pre-
treated with milrinone to explore in principle whether
PDE3A inhibition might diminish prothrombotic effects
of oxLDL. Consistent with previous studies, modulation
of PDE3A activity reduced murine thrombosis (Figure 6A-
C).23 Importantly, the presence of milrinone (10 mmol/L)
significantly reduced the ability of oxLDL to promote
thrombosis at all time points post injury (P<0.05) (Online
Supplementary Video S3) suggesting the heightened throm-
botic response in the presence of  oxLDL could be related,
at least in part, to changes in PDE3A activity.
Discussion
The presence of oxidized lipid epitopes, including
oxLDL, is thought to promote platelet hyperactivity in
subjects with obesity, CAD and stroke.5,6,35 It has been
established that oxidative modifications are a hallmark of
dyslipidemia and that they stimulate platelet activation
directly through a number of distinct receptors.6,8,13
Interestingly, platelets from patients with CAD and dys-
lipidemia show a reduced sensitivity to the inhibitory
effects of PGI2. These observations, coupled to pharmaco-
logical trials indicating that suppression of endothelial
PGI2 synthesis increased rate of atherothrombotic
events,36–39 suggest that platelet sensitivity to PGI2 could
play an undefined role in the development of
atherothrombotic events. Hence, the aim of this study
was to investigate whether oxLDL may promote unwant-
ed platelet activation through the modulation of platelet
sensitivity to PGI2. Using a combination of pharmacologi-
cal and genetic approaches, we show that oxidative lipid
stress modulates platelet cAMP signaling leading to
increased platelet activation.  Our key findings include: (i)
oxLDL and oxidized phospholipids decrease platelet sen-
sitivity to PGI2, which is coupled to reduced platelet accu-
mulation of cAMP and PKA mediated signaling; (ii) PGI2
hyposensitivity likely occurs via sustained activation of
the cAMP hydrolysing enzyme PDE3A in response to
oxLDL; (iii) the activation of PDE3A by oxLDL requires
ligation of CD36; and (iv) that dyslipidemia induces
platelet hyposensitivity to PGI2 in a CD36-dependent
manner.  
CD36 activates platelet PDE3A
haematologica | 2020; 105(3) 817
In the first instance, we used three increasingly physio-
logical systems to show that exposure of platelets to
oxLDL opposes the inhibitory effects of PGI2. In contrast,
oxLDL failed to affect platelet inhibition by 8-CPT-6-Phe-
cAMP, a PDE-resistant cAMP analog, demonstrating firstly
that the PKA signaling was intact and secondly that the
effects of the oxidized lipoprotein may regulate cAMP
availability.  Exploration of the underlying mechanisms
demonstrated that OxLDL prevented the accumulation of
cAMP in response to both PGI2 and forskolin. Forskolin
increases cAMP in a receptor-independent manner, there-
by providing evidence that oxLDL did not affect the inter-
action of PGI2 with the IP receptor or target adenylyl
cyclases. This is consistent with previous studies demon-
strating that reduced platelet sensitivity to PGI2 in patients
with hypercholesterolemia was independent of any
changes in cAMP synthesis by adenylyl cyclase.36 It was
therefore possible that oxLDL could either prevent the
synthesis of cAMP or accelerate its breakdown. We fur-
ther found that oxLDL failed to modulate cAMP concen-
trations in the presence of the PDE3 inhibitor milrinone,
but not the PDE2 inhibitor EHNA, suggesting that cAMP
hydrolysis by PDE3A was the potential mediator of PGI2
hyposensitivity. A role for PDE3A was confirmed using
immunoprecipitation experiments showing that both
oxLDL and oxPCCD36 accelerated the hydrolytic activity
of PDE3A in both human and murine platelets through lig-
ation of CD36. The activation of PDE3A downstream of
CD36 required the activation of Src family kinases, Syk
and PKC. This provides further evidence that CD36-SFK-
Syk represents a multiprotein complex that transduces
extracellular oxidative lipid stress to the intracellular sig-
naling machinery of the platelet. Interestingly, hemostatic
agonists such as thrombin and collagen also activate
PDE3A through a PKC-dependent mechanism.31 These
agonists are proposed to cause a rapid attenuation of
cAMP signaling at sites of vascular injury to promote
platelet-mediated hemostasis. However, in contrast to the
rapid and short-lived activation of PDE3A activity by
thrombin and collagen, oxLDL induced a sustained
PDE3A response for up to 60 min (longest time tested).
This was linked to a different activatory phosphorylation
pattern of PDE3A by oxLDL and could suggest a distinct
mechanism of activation induced by short-lived hemosta-
tic agonists from that of oxLDL. Given the sustained acti-
vation of platelet PDE3A in the presence of oxidative lipid
stress, it is attractive to speculate that PDE3A may be par-
tially activated in dyslipidemic disease states and thereby
reduce the threshold for platelet activation by diminution
of cAMP. Indeed, gain of function mutations of PDE3 are
associated with stroke, underlining its role in vascular
pathology.40 This concept is also supported by observa-
tions that inhibition of PDE3A by cilostazol can have ben-
eficial anti-thrombotic effects in high-risk groups charac-
terized a prothrombotic phenotype.41–43 
The pathophysiological consequences of platelet
hyposensitivity to PGI2 and the potential importance of
CD36 was explored in a murine model of high-fat feed-
ing-induced dyslipidemia. Interestingly, we found that
even mild dyslipidemia was characterized by the presence
of oxidized lipid epitopes in the plasma, which was unaf-
fected by the absence of CD36. Whole blood phospho-
flow cytometry was used to measure platelet
phosphoVASP, as a marker of cAMP signaling, without the
need for cell isolation. This demonstrated that mild dys-
lipidemia was accompanied by reduced cAMP signaling.
The functional importance of this blunted cAMP signaling
response manifested as diminished platelet sensitivity to
the inhibitory effects of PGI2 on integrin activation meas-
ured by flow cytometry and ex vivo thrombosis. The
assessment of thrombosis ex vivo was important to
demonstrate that hyposensitivity of platelets to PGI2 was
a primary platelet defect rather than a response to a dys-
functional endothelium, where altered PGI2 production
has been observed in models of dyslipidemia.32 To support
our hypothesis that hyposensitivity to PGI2 was linked to
PDE3A activity, we showed that cAMP signaling in dys-
lipidemia was normal if a PDE-resistant cAMP analog (8-
CPT-6-Phe-cAMP) was used, again confirming that PKA
signaling downstream of cAMP was functional. Critically,
genetic ablation of CD36 protected animals from the loss
of PGI2 sensitivity and restored PKA signaling.  Infusions
of oxLDL into wild-type mice caused a robust potentia-
tion of thrombosis by ferric chloride. However, mice were
protected from the prothrombotic effects of oxLDL in vivo
when PDE3A was pharmacologically inhibited. Using this
approach, milrinone did not target only platelets and could
therefore have an effect on other PDE3A expressing cells.
However, the data are proof of principle that the pro-
thrombotic effects of oxLDL in vivo, at least in part, may
be prevented by therapeutic strategies based on enhancing
or preserving cAMP signaling events in platelets. This ele-
ment of the work requires further studies focussing on
strategies for the specific targeting of PDE3A, and poten-
tially PDE2, in platelets. 
Together, our ex vivo and in vitro data suggest a previous-
ly unrecognized mechanism contributing to platelet
hyperactivity, where the ligation of CD36 by oxidized
lipids modulates cAMP signaling by activating PDE3A
leading to PGI2 hyposensitivity. These data may constitute
a link to the observed PGI2 hyposensitivity in dyslipidemic
high-risk populations and indicate a novel therapeutic
strategy to target atherothrombotic risk in certain patient
groups. Remarkably, current antiplatelet therapy exclu-
sively targets platelet activatory pathways including
cyclo-oxygenases (Aspirin), P2Y12 (Thienopyridines, non-
Thienopyridines) or αIIbβ3 (Tirofiban; Eptifibatide) while
platelet inhibitory pathways remain untargeted.
Therefore, high-risk populations might remain at
increased atherothrombotic risk despite optimal available
pharmacological therapy, and impaired platelet inhibition
might contribute to the residual cardiovascular risk. 
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